Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 22202153)

1.

Actinium-225 in targeted alpha-particle therapeutic applications.

Scheinberg DA, McDevitt MR.

Curr Radiopharm. 2011 Oct;4(4):306-20. Review.

PMID:
22202153
2.

Radioimmunotherapy with alpha-particle emitting radionuclides.

Zalutsky MR, Pozzi OR.

Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96. Review.

3.

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Miederer M, Scheinberg DA, McDevitt MR.

Adv Drug Deliv Rev. 2008 Sep;60(12):1371-82. doi: 10.1016/j.addr.2008.04.009. Epub 2008 Apr 23. Review.

4.

Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.

Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA.

J Nucl Med. 2014 Sep;55(9):1492-8. doi: 10.2967/jnumed.114.138347. Epub 2014 Jun 30.

5.

Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.

Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S.

Cancer Biother Radiopharm. 2002 Apr;17(2):219-31.

PMID:
12030116
6.

Targeted alpha therapy: part I.

Elgqvist J.

Curr Radiopharm. 2011 Jul;4(3):176.

PMID:
22201706
7.

Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.

Vaidyanathan G, Zalutsky MR.

Curr Radiopharm. 2011 Oct;4(4):283-94. Review.

8.

The promise of targeted {alpha}-particle therapy.

Mulford DA, Scheinberg DA, Jurcic JG.

J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S. Review.

9.

The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.

Geerlings MW, Kaspersen FM, Apostolidis C, van der Hout R.

Nucl Med Commun. 1993 Feb;14(2):121-5.

PMID:
8429990
10.

Molecular targeted α-particle therapy for oncologic applications.

Wadas TJ, Pandya DN, Solingapuram Sai KK, Mintz A.

AJR Am J Roentgenol. 2014 Aug;203(2):253-60. doi: 10.2214/AJR.14.12554. Review.

PMID:
25055256
11.

Tumor therapy with targeted atomic nanogenerators.

McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA.

Science. 2001 Nov 16;294(5546):1537-40.

12.

Radioimmunotherapy with alpha-emitting nuclides.

McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA.

Eur J Nucl Med. 1998 Sep;25(9):1341-51. Review.

PMID:
9724387
13.

Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases.

Chang MY, Seideman J, Sofou S.

Bioconjug Chem. 2008 Jun;19(6):1274-82. doi: 10.1021/bc700440a. Epub 2008 May 28.

PMID:
18505278
14.

Radionuclides for radioimmunotherapy: criteria for selection.

Geerlings MW.

Int J Biol Markers. 1993 Jul-Sep;8(3):180-6.

PMID:
8277210
15.

Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.

Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A, Sgouros G.

Cancer Res. 2009 Dec 1;69(23):8941-8. doi: 10.1158/0008-5472.CAN-09-1828. Epub 2009 Nov 17.

16.

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.

Clin Cancer Res. 2004 Jul 1;10(13):4489-97.

17.
18.

Design and synthesis of 225Ac radioimmunopharmaceuticals.

McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA.

Appl Radiat Isot. 2002 Dec;57(6):841-7.

PMID:
12406626
19.

Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides.

Henriksen G, Schoultz BW, Michaelsen TE, Bruland ØS, Larsen RH.

Nucl Med Biol. 2004 May;31(4):441-9.

PMID:
15093814
20.

Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.

Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, Davis IA, Stabin M, Mirzadeh S.

Cancer Biother Radiopharm. 2000 Jun;15(3):235-44.

PMID:
10941530
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk